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ABSTRACT 
The skin is a barrier which protects us against daily attacks of foreign substances. 
From a pharmaceutical perspective it is also an interesting delivery route with its large 
surface and possibility to reach the blood stream circumventing first passage 
metabolism. With the varied size, structure etc. of active pharmaceutical substances, 
as well as the structure and function of the tissue, skin penetration is challenging. 
 
The work included in this thesis mainly focus on exploring the lipid based cubic 
liquid crystalline phases as dermal drug delivery vehicles. Of particular interest has 
been systems based on glyceryl monooleyl ether (GME), while cubic phase 
containing glyceryl monooleate (GMO) and water was used as reference system. 
These lipids and cubic phases are very similar but an important difference is that 
GME requires a solvent to form a cubic phase in excess water while GMO does not. 
The cubic phases made of GME, are less studied but have potential to be effective 
dermal delivery vehicles. The phase behavior of the GME systems has been 
thoroughly investigated and the dermal delivery of active compounds from the cubic 
formulations evaluated. Examples of the methods used are small angle X-ray 
diffraction, in vivo fluorescence spectrophotometry, two photon microscopy, and high 
performance liquid chromatography. 
 
The GME-based formulations showed to be as good as the GMO-based cubic phase 
for dermal delivery of small molecules. The cubic formulations significantly enhanced 
the delivery, both in amount and depth, compared to a commercial product. For larger 
molecules and nanoparticles, however, skin penetration was found only when a GME-
based cubic formulation was used as delivery vehicle. 
 
Through combining all obtained results, a hypothesis of the dermal delivery 
mechanism was formed. The skin adherence and the occluding and hydrating effects 
of the formulations are important for effective delivery. However, the phase behavior 
of the formulations is also important to explain the mechanism. The GME-based cubic 
phase turns into a reversed hexagonal phase in excess water, whereas the GMO-based 
formulation maintains its cubic structure. This small but significant difference may be 
the reason for the difference in ability to deliver larger molecules and particles into 
skin. 
 
Keywords: liquid crystalline phases; cubic phase; reversed hexagonal phase; dermal 
drug delivery; glyceryl monooleat; glyceryl monooleyl ether; pentane-1,5-diol; 
propylene glycol; N-Methyl-2-pyrrolidone  
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INTRODUCTION 
In this thesis, I strive to put the research into a wider context and to 
create a knowledge platform for a discussion of my results. However, the 
reason for the project and the main research questions are most easily explained 
through a specific story. 
 
The story begins at the department of dermatology at Sahlgrenska University 
Hospital, where Professor Jan Faergemann found out that an interesting 
antimycotic diol (pentane-1,5-diol, POL) was able to enhance dermal drug 
delivery. POL had previously not been used for skin formulations and Jan 
wanted to investigate the enhancing qualities of the substance further. 
 
Meanwhile, at pharmaceutical technology, Chalmers University of Technology, 
Professor Sven Engström and his PhD -students were working with liquid 
crystalline phases, both characterizing them and investigating their abilities as 
drug delivery vehicles. During this research they came in contact with 
Associate Professor Marica Ericson who has extensive knowledge of advanced 
imaging techniques and their use for investigating skin diseases such as cancer. 
In a joint project they examined the use of the cubic phase as a drug delivery 
vehicle in photodynamic therapy (PDT), a treatment method for superficial 
forms of skin cancer. They found that the cubic phase significantly enhanced 
the diffusion of active substance into the cells. However, there were problems 
encountered, for example both the drug and the formulation had stability issues. 
 
Through the center for skin research (SkinResQU) in Gothenburg, Jan, Sven 
and Marica met one another. By combining their separate questions and 
competences a new research project was born and I started my PhD studies.  
 
My work started with comparing POL with the known permeation enhancer 
propylene glycol (PG) for increased delivery of terbinafine to the upper skin 
layers (paper I). POL showed to be an efficient permeation enhancer in the 
hydrogel used as a delivery vehicle, and as POL is an apolar diol it was also of 
interest as a component in liquid crystalline phases. Liquid crystalline phases 
1
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are molecularly ordered structures which can be formed by polar lipids, such 
as, glyceryl monooleate (GMO) and glyceryl monooleyl ether (GME) in 
presence of water. GMO forms a cubic phase in excess water while GME and 
water results in the reversed hexagonal phase. An apolar solvent can be used to 
reach specific liquid crystalline phases to, for example, form the cubic phase in 
the GME-water system. Included in this work were two different types of cubic 
formulations in excess water, the well-known GMO-water based system and 
the less investigated GME-solvent-water based system. The phase behavior of 
two systems composed of the lipid GME, water, and one of the solvents POL 
or N-Methyl-2-pyrrolidone (NMP) was thoroughly investigated (paper II). 
 
With a commercial interest, improved versions of the delivery system for use in 
PDT were sought and found in the combination of GME, water, and POL or 
PG. By exchanging the lipid of the cubic phase formerly used and including 
one of the solvents, the stability issues of the previous system were solved and 
an on demand cubic formulation was obtained. The diffusion of the active 
substances from the formulation into skin tissue was investigated in vivo and 
showed good results (paper III). Despite the good results the commercialization 
process was terminated so that publication of the work was enabled. 
 
In order to find out how effective this formulation is for dermal delivery, 
protein (bovine serum albumin, BSA) and nano-particles (quantum dots, QD, 
and gold nanoparticles, AuNP) were tested as model drugs. When AuNP in 
cubic formulation were applied to the skin and analyzed using two-photon 
microscopy (TPM), the particles could not be detected due to optical 
phenomena. This led to a digression into technical and physical aspects of the 
occurrences. However, other nano-sized particles and protein could be found 
within the skin when the solvent containing on demand formulations were used 
(paper IV). 
 
As can be seen from the contents of the research described, there has been a 
clear goal to enhance dermal drug delivery by exploring cubic formulations as 
a delivery system. However, it is of course also important to understand the 
underlying mechanisms of the interaction between formulation and skin. In 
order to find even more clues to this puzzle, an attempt was made to locate the 
lipids of the formulation among the lipids of the skin and thus coherent anti-
-3- 
Stokes Rahman spectroscopy (CARS) was employed. The results showed that 
GME penetrated around the cells and was in part found as droplet-shaped 
depots within the tissue. 
 
The results obtained in the different studies all contributed to the formation of a 
hypothesis regarding the dermal drug delivery mechanism. The cubic phase 
formulations are very similar in most aspects. However, the phase behavior and 
the ability to deliver larger molecules and particles differ. The postulated 
hypothesis takes both similarities and differences into account and will be 
further discussed in Chapter 3.4. 
 
However, prior to this, the research field is described through the description 
of, for example, the skin structure and function and dermal drug delivery in 
Chapter 2. With these facts in mind the reasons for choosing the nano-
structured cubic phase as a delivery vehicle are revealed. The configurations of 
the liquid crystalline phases are presented, as well as their relation to each 
other. Further, the phases as carriers of active substance are described, where 
after the combination of cubic formulation, pharmaceuticals and skin are tied 
together (Chapter 3). Throughout the work a number of techniques have been 
used for assessment. These are described in Chapter 4. Lastly, the thesis is 
concluded by presenting the results of the performed studies and the impact of 
them on the hypothesis, followed by future research ideas (Chapter 5-7). 
-4- 
  
-5- 
 
DERMAL DRUG DELIVERY 
This chapter deals with skin structure and functions as well as the 
delivery of active pharmaceutical ingredients (API) into the skin tissue. In 
order to be able to suggest a delivery mechanism these are important areas to 
have knowledge about. 
2.1. DRUG DELIVERY TODAY 
2.1.1. DELIVERY ROUTES 
Anyone in our modern society who has ever had a cold or any kind of illness 
has used pharmaceuticals of some sort. The most common administration 
routes for drug delivery, depicted in Figure 1, are oral, pulmonary (via the 
lungs), parenteral (piercing skin or mucus membranes), and topical (via body 
surfaces; skin or mucus membranes such as vagina, anus, throat, eyes, nose, 
ears). There are a number of reasons why a certain route and a certain 
formulation is chosen for a specific drug. Firstly, it must be decided if the drug 
should have a local or a systemic effect. Secondly, physical and chemical 
properties of both the drug and the additives must be understood and addressed 
as well as factors influencing drug absorption and release [1, 2]. 
 
Here the focus lies on dermal drug delivery which is a part of the fourth route 
mentioned – the topical route. The term dermal delivery is often confused with 
transdermal delivery. However, throughout this text dermal delivery will be 
referred to for delivery into the skin tissue while transdermal delivery enables 
penetration through the skin and into the blood stream. 
 
Dermal delivery typically has a very high patient compliance [3]. The few 
occurring side effects can normally be circumvented simply by changing 
administration site [4, 5]. Although the delivery may at times be both poor and 
erratic, it can be controlled and sustained over a prolonged period of time [6] 
and with more research the drug delivery is improving. The large variability in 
2
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tissue thickness and permeability between individuals, and more importantly 
between healthy and diseased skin can cause problems with regard to drug 
delivery [7]. Topical delivery is often used to achieve a local effect, but it is 
also possible to aim for systemic uptake. As with injections and inhalation, the 
first passage effect is circumvented and, additionally, the drug application is 
easy and pain free [1]. 
 
 
Figure 1 Schematic image showing examples of drug delivery routes. 
2.1.2. ACTIVE INGREDIENTS IN THE FORMULATIONS 
Current active pharmaceutical ingredients (API) tend to have larger, more 
complex, and less soluble molecular structures. This, of course, must be dealt 
with. One method is to turn the drug into a salt. This can also help stabilizing 
an easily degradable drug, for example a protein [8]. 
 
The formulations holding the drug must be able to contain and deliver the API, 
regardless of their respective difficulties and chosen delivery route. If the 
galenic approach is chosen wisely the drug can be aided to work as efficiently 
as possible. In topical treatment this is particularly difficult, as the main focus 
is to get the drug through the tissue. In paper III-IV dermal delivery of a highly 
degradable substance and large molecules are handled. This will also be 
discussed further in Chapter 3.2. 
 
When comparing and interpreting dermal delivery data obtained in different 
studies it is important to be aware of the possible variations in methodology, 
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including type of equipment used, skin temperature, and skin treatment [9]. 
Caution is of great importance as is a substantial knowledge about skin 
structure and function. The skin structure and function also comes in to play 
when designing a well working topical drug delivery system. 
2.2. THE LAYERED STRUCTURE OF THE SKIN 
If you look down at the hands holding this thesis you will see skin. Depending 
on your size, you are covered with around 1.5-2 m2 of the tissue. For long the 
skin was regarded as nothing more than what keeps our insides in place, but as 
research took off, our largest organ proved to have fascinating features. The 
skin is a barrier against environmental attacks such as UV radiation, chemicals 
and microbiological factors. Additionally, one of our five senses is located in 
the skin: the ability to feel pain or the slightest touch both protects us and 
increases the quality of life. Furthermore, controlling the amount of internal 
water and body temperature is maintained by the skin. Also worth mentioning, 
the essential vitamin D is here produced in a photo-driven reaction [10]. 
 
 
Figure 2 A schematic illustration of the skin and its layers. 
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The skin is divided into three main layers: epidermis, dermis, and subcutis 
(Figure 2). Each layer has functions of its own. For warmth and comfort, the 
fatty tissue of the subcutaneous layer provides insulation and padding. Subcutis 
is located closest to the muscle tissue with dermis on the outside. Dermis 
provides elasticity to the skin through collagen and elastic fibers, and contains 
for example, nerve cells, hair follicles, and glands (see Figure 2). Epidermis 
forms the skin surface and prevents water loss. Because of this vital function it 
is also the most prominent obstacle in transdermal drug delivery. Thus, it is the 
most important to understand in order to solve the obstacles encountered when 
administering APIs via the skin. 
 
Epidermis is divided into layers based on keratinocyte cell differentiation: 
stratum basale (SB), stratum spinosum (SS), stratum granulosum (SG) and 
stratum corneum (SC). Figure 3 [11] illustrates the different skin layers both as 
a schematic drawing and as two-photon microscopy (TPM) images (further 
detail regarding the methodology will presented in Chapter 4.3.). In SB the 
keratinocyte cells are formed and they migrate towards the skin surface 
becoming flatter the further out they get. When the keratinocyte cells have lost 
their nucleus, once they reach SC, they are referred to as corneocytes. At the 
surface these cells are dead and eventually peel off leaving room for the cells 
following in a slow but never-ending migration of cells [10]. 
 
 
Figure 3 Two-photon microscopy images of normal skin. SC (0 mm), SS (15 mm), SB (30 mm), 
dermal papillae (DP) (45 mm), and dermis (75 mm) are visualized (images published with 
permission [11]). Below figure: a schematic illustration of depth location of the respective layers. 
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The structure of SC is often compared to a brick wall, where the corneocytes 
are the bricks and the lipids surrounding them the mortar [12]. The main lipids 
forming the mortar are ceramides (CER), cholesterol (CHOL) and free fatty 
acids (FFA) (Figure 3b), composed in such a defined way that alterations can 
affect membrane integrity [13-19]. This composition is not found in many other 
biological membranes, especially as it practically lacks phospholipids [20]. The 
complexity of the lipid matrix is indicated in the fact that more than 300 
species of ceramides alone have been identified therein [21]. How the lipids are 
organized is a complex matter, but in the late 1980s and early 1990s, it was 
concluded that there is an ordered structure [22-24] and that different fractions 
of the lipids can be found in both a liquid and solid state [19, 23, 25-29]. 
 
In 1994, Forslind presented the “domain mosaic model” which suggests that 
the lipid matrix is composed of lipid moieties mainly in the crystalline/gel state 
with a small amount of fluid state lipids between these domains [25]. This 
model is an interesting starting point for the hypothesis presented later (Chapter 
3.4.). It has been shown that the main part of the SC lipids is rigid at 32°C with 
a small amount of fluid lipids present [30]. Lamellar and reversed hexagonal 
liquid crystalline phases have been found to exist [31], and by influencing the 
borders of the rigid parts, for instance by hydration or diffusion of solvents, 
other phase changes may occur. However, it is important to stress that the lipid 
matrix is an important part of the skin barrier properties with a structure 
hindering substance migration [19, 32]. 
 
Recently the group of Norlén and coworkers published a study of the SC matrix 
structure using mainly cryo-electron microscopy. They found that the lipid 
bilayers are a stacked structure of fully extended ceramides with cholesterol 
associated to specific parts [15]. The presence of alternating hydrophilic head 
groups and hydrophobic alkyl chains in this crystalline-like (gel-like) pattern 
would result in a matrix principally impermeable to water, as well as 
hydrophobic and hydrophilic substances [19, 32]. It would also result in the 
possibility for layers to slide against each other to some extent, thus 
maintaining the barrier while providing flexibility [15]. 
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RELATED FACTS BOX – SKIN DIMENSIONS 
 
It can be hard to relate to the tiny sizes and dimensions of the skin, so let us put 
them into perspective! 
 
The upper part of the skin consists of, in average, 10 layers of cells which are 
roughly 1 µm high and 40-50 µm long [33]. Seen from the side, in cross 
section, it looks like the bricks in a brick wall (see Figure 2 above), though 
much longer and flatter. All around the cells, like mortar, we have the lipid 
matrix which is about 35 nm thick [15]. 
Figure 4 One km of road E20 surrounded by refrigerators envisions the dimensions of one cell 
and the lipid matrix in SC. 
Let us stop there and imagine the following: Pretend that the cells are as wide 
(~20 m) and long as one km of road E20 (of the Europe international E-road 
network). Then fancy the lipid matrix as a lot of refrigerators lined up on the 
edge of the road (See Figure 4). Now, stack the part of road, with refrigerators 
around, like a brick wall and you may find it easier to relate to the dimensions 
of the SC skin structure… hopefully   
-11- 
2.2.1. THE LIPID MATRIX 
As this lipid matrix plays such an important role in the dermal drug delivery 
and possibly in the interaction between the cubic formulations and skin (paper 
IV and Chapter 3.3.), I wish to further discuss the sizes and structure of this 
barrier.  
 
In Figure 5 we see some of the results from the work of Iwai et al. [15]. From 
the top down: the lipid matrix between cells in SC, the distances of the 
repeating units within the matrix, and a schematic model of how the CER, 
CHOL and FFAs are situated to build this structure. 
 
Figure 5 The SC lipid matrix as depicted by Iwai et al. (a, published with permission [15]) and 
examples of the molecular structure of a CER, CHOL and FFA (b, from the top down). 
 
The lipid matrix is shown as lamellar regions with 2-12 dark lines, 6 lines on 
average. This would imply that the thickness (or height) of the matrix would be 
between ~10-60 nm. As anything passing in or out of the skin must pass this 
lipidic continuum, the dimension of it is important. Moreover, the bilayered 
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organization of the lipid matrix helps to reduce the permeability over the 
membrane [34], in other words this polar - non-polar - polar molecular 
composition in gel state forms an efficient barrier structure. 
 
The schematic model depicted in Figure 5 is based on a bare minimum of 
molecules, indicating that if all the CER, CHOL and FFAs existing in SC were 
included, the structure of the lipid matrix would most likely be less compact 
and more adaptable. One interesting aspect of this is that only a small amount 
of fluid lipid added to gel-like parts of a bilayer alters the permeability [34]. 
 
The water transport through our skin is vital and the trans-epidermal water loss 
is ~250 ml/day for adults. At normally hydrated conditions the lipid matrix is 
winding between the cells. At increased hydration, however, water causes the 
cells to swell and the lipid matrix is thus flattened. The thickness of the lipid 
continuum seems unaffected indicating no increase of water therein [15].  
2.2.2. CELLS IN EPIDERMIS 
The second most abundant cells in epidermis, after keratinocytes/corneocytes, 
are the Langerhans cells. The Langerhans cells are potent antigen-presenting 
cells that are part of the immunological surveillance and effector system in our 
bodies. These cells can be of importance for the work presented in paper IV, as 
proteins delivered into the skin may be further transported to the immune 
system by the Langerhans cells. The cells that produce the pigment melanin are 
called melanocytes. Melanocytes protect the nucleus of basal keratinocytes 
from UV radiation. Merkel cells are sensory receptors that are in contact with 
nerve fibers in the dermal skin layer [1, 10]. 
2.3. DERMAL DELIVERY METHODS 
Historically, skin diseases have been treated using herbal medicines with 
different outcomes. Some of the ancient knowledge has been forgotten and 
some reinvented, but when it comes to modern formulations for systemic 
treatment it took until 1979 to get a product out on the market. It started with a 
patch for motion sickness (Transderm Scop) and continued with pain relief, 
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hormone treatments and nicotine cessation. Recently, the focus has shifted 
more towards treating, for example, Alzheimer’s, Parkinson’s and dementia 
using the transdermal administration route [35, 36]. 
 
Drugs within the classical dermal delivery boundaries (see Table 1) are most 
often incorporated into hydrophobic ointments or semi-solid emulsions such as 
creams and gels [1]. The latter examples are just as often used in cosmetic 
applications making the penetrative abilities of the active ingredient somewhat 
questionable. Cosmetic products can moisturize the skin and treat superficial 
problems, for example, making the line between pharmaceutics and cosmetics 
unclear in some cases. Also, formulation ingredients used as penetration 
enhancers in a pharmaceutical system can be used as moisturizer in a cosmetic 
product. One interesting example, which is relevant for the work presented 
here, is propylene glycol (PG). PG is frequently used in both cosmetics and 
pharmaceuticals. It has even been used on its own to treat dandruff and various 
other skin issues such as fungi infections and inflammations due to its 
humectant and antibacterial properties [37]. However, it is the final delivery 
result that decides if the product will be approved and not the included 
components (as long as they are within regulations). 
 
Dermal drug delivery can appear to be a simple form of treatment at first 
glance. Though a closer assessment reveals that a proper dermatological design 
is one of the most challenging tasks to tackle within the galenic formulation 
field [1]. The complex nature of the skin and the fact that it is a barrier 
protecting our bodies against any outer attack ensures that there will be 
numerous difficulties to conquer in order to achieve a well-functioning 
formulation. 
2.3.1. LIMITATIONS AND POSSIBILITIES 
With regards to the properties of the substance to be delivered, there are some 
traditional guidelines that are recommended to follow in order to successfully 
deliver the drug into the skin. These boundaries, summarized in Table 1, might 
not always be valid [35] but can at least provide a good starting point. 
 
-14- 
Table 1 Traditional limitations and boundaries for transdermal drug delivery 
   Partition coefficient       1 < log Ko/w < 3 
   Molecular weight       < 500 Da 
   Melting point       < 200 °C 
   Daily dose       < 10 mg 
   Solubility (H2O)       > 1 mg/ml 
   pH       5-9 
 
Research is important in order to increase the possibilities for transdermal 
delivery. For example, one of the limitations mentioned in Table 1 is the size of 
the molecules that can be delivered transdermally. This is a difficult obstacle to 
address [36]. However, in our research we found that by using the instantly 
formed lipid-water based cubic formulation (presented in detail in Chapter 
3.3.2.) as a delivery vehicle, larger APIs (5 – 20 nm) may be transported into 
the tissue (paper IV). Both nanoparticles and a model protein (bovine serum 
albumin, BSA) were delivered into viable epidermis (paper IV and Chapter 
5.5.). Thus, despite the very real barriers and boundaries, a suitable formulation 
may be a solution to the problem. 
 
The formulation can have different delivery aims depending on what API will 
be administered. An active substance treating the skin itself should stay in the 
outer layers of the skin. It is possible to achieve a depot effect and thus provide 
a prolonged release, which has been seen for the cubic phase [38]. Such a depot 
can also induce a systemic effect over time. 
 
In transdermal delivery the drug must reach deeper into the tissue. The 
pharmaceutical concentration is very high at the application site on the skin 
surface and very low or non-existing further in. There is much blood present 
deep in the skin acting as sink for the diffusing molecules. The effect of this is 
a high epidermal concentration gradient driving a percutaneous absorption [1]. 
 
The possible ways for the drug to move into the skin is limited, as well as 
debated. One pathway is through the lipid matrix surrounding the cells [39]. 
Here the fluid parts of the lipid matrix are crucial for enabling transport of 
lipophilic and amphiphilic substances, as discussed above. A second route is 
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more resistant but possible and leads through lipidic parts of cell membranes. 
Further, a transcellular pathway is also considered but has been questioned and 
regarded unlikely by some as the transported substance must pass in and out of 
water and lipid rich regions [40, 41]. Finally, a combination of these pathways 
is also likely depending on the drug, the formulation and the skin tissue [42]. In 
other words, restricting the route to, for instance, only the lipid domains might 
be unreasonable due to the very small space [43]. The water rich skin cells, 
corneocytes, are enclosed within so-called cornified envelopes consisting of 
cross-linked proteins with a monolayer of lipids linked to it [44]. Between the 
cells the lipid matrix is the only continuum and hence, beyond question, all 
molecules passing in or out of the skin must pass this lipid domain sooner or 
later [42, 45-47]. To some extent, hair follicles can also be a possible way in to 
the skin [48] but from the bottom of the follicle the drug must still be 
transported further to be of therapeutic use elsewhere. 
2.3.2. FORMULATION APPROACHES 
The historically most common dermal formulation approach is to use oil, 
emulsifier and water (o/w, w/o, etc.), and thus obtain emulsions such as creams 
and lotions [1, 49]. Interestingly there are often no differences between 
formulations with a pharmaceutical aim and cosmetic products. As an example, 
liposomes and lipid nanoparticles are used in cosmetic products and were 
actually first found on the cosmetic market before they were used aiming to 
dermally deliver drugs [50]. This is quite a contradiction because the medical 
formulations need to deliver the drug into the skin tissue while cosmetics are 
not allowed to enter the body [1, 49]. An effective dermal delivery, based on 
the same systems as are present in a cosmetic product, thus seems unlikely. 
 
A lot of research focuses on enhancing the skin permeation in a number of 
different ways. Table 2 lists some of the more widely used methods of which a 
few (Figure 6) will be explained below in order to paint a clearer picture of the 
field of dermal drug delivery. 
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Table 2 Methods for dermal drug delivery enhancement. 
Methods Examples 
Electrical Iontophoresis, Electroporation 
Mechanical Microneedles, suction, stretching 
Other device-dependent Ultrasound, temperature changes, laser, patches 
Chemical Enhancers, lipid-based vehicles, water gradient changes 
2.3.2.1 MECHANICAL METHODS 
The effects of electric current applied to skin for treating diseases or relieving 
pain have been recognized for at least 5,000 years when electrical eels were 
used for this purpose [51]. The techniques have been developed since then and 
used in a wide variety of pharmaceutical applications. For dermal delivery of 
drugs iontophoresis is one recent example. In iontophoresis a power source and 
two electrode compartments drive ionized drug molecules into the skin, as 
shown in Figure 6a. The device is connected to the skin, and once the current is 
applied the positive charges in the anodal compartment move towards the 
cathode and the anions move in the opposite direction. As the only way to 
move is through the skin the drugs are forced into the tissue [52]. 
 
Microneedles are considered a mechanical method of administration. They are 
minimally invasive and are being developed in different materials and with 
different delivery strategies. The main application has been to make 
microscopic holes in the skin and then apply a transdermal patch or other drug 
container to the perforated area. Sometimes iontophoresis are used in 
combination with microneedles. The drug can be located in cavities within the 
needles, the tips can be dipped in drug solution, or the drug can be incorporated 
in biodegradable needles so that when piercing the skin or when the needles 
break down the drug is released (see Figure 6c) [53]. 
 
Sonophoresis uses ultrasound to enhance transdermal transport of various drugs 
through, for example, heating and skin disruption (Figure 6b). Ultrasound has 
been used in different frequency ranges, but it has been found that low 
frequencies (<100kHz) are more effective in drug delivery than higher 
frequencies [54].  
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Figure 6 Schematic illustration of device driven dermal drug delivery showing (a) iontophoresis 
with delivery electrode and counter electrode, (b) sonification, (c) microneedles, (d) and a drug 
delivery patch. 
2.3.2.2. NON-INVASIVE METHODS 
Patches are often combined with other techniques such as those used after 
iontophoresis or as a micro-needle array patch [55, 56], but a lot of resources 
are spent on improving the patch itself. Patches are becoming more and more 
important in transdermal drug delivery. The traditional components in a patch 
are a liner, drug reservoir of some sort, adhesive, membrane, and backing 
(Figure 6d). Some patches include all of these parts and some do not, but either 
way all are developed to hold and deliver the API and to make the skin more 
susceptible to the it [56]. Today, besides the previously mentioned patch for 
motion sickness, there are patches for nicotine delivery and pain relief, for 
instance. Moreover, specific diseases are being targeted such as Alzheimer’s 
[57] and Parkinson’s [58], additionally patches are developed for vaccine 
delivery [55]. 
 
There are a number of classical non-invasive formulations such as ointments, 
creams, pastes, gels, suspensions, and solutions, which merely work for 
molecules within the boundaries presented in Table 1. When aiming for 
increased dermal delivery of anything else high demands are placed on the 
formulation. In the previous section invasive methods were presented. 
However, there are a number of down-sides of using these methods, including 
mechanically disrupting the skin surface, high manufacturing expenses, drug 
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degradation during storage or production [52, 59]. Therefore, it would be 
desirable to find less invasive delivery methods that are still effective. 
 
One interesting group of formulations is the nanostructured lipid based liquid 
crystalline systems (further discussed in Chapter 3), which can have, for 
example, adhesive features, be engineered to provide sustained delivery, and 
can contain a wide variety of drugs [60-63]. Thus, these formulations can be 
good candidates for dermal drug delivery [61, 62, 64-67]. 
 
The consistency of a dermal formulation should be acceptable to the user and 
stay in place in order to interact with the skin and efficiently deliver the API. 
Some liquid crystalline phases fill these criteria better than others. The gel-like 
phases such as cubic and reversed hexagonal have better application qualities 
than the less viscous formulations such as lamellar and sponge phase. 
Furthermore, from a drug release view the cubic phase has a faster release rate 
than the reversed hexagonal one. 
 
Moreover, because of the skin structure, any vesicle able to penetrate must be 
deformable and fluid in the lipid bilayers [68]. Delivery vehicle interaction 
with the skin lipids can influence a phase change so that more of the solid lipid 
sections of the intercellular matrix become fluid, thus enabling enhanced 
molecular diffusion [69]. 
 
The liquid crystalline phases can be formed into small, nanosized particles: 
liposomes, hexosomes and cubosomes [64, 70]. The drugs are incorporated into 
these vesicles. Still not many reach a sufficient administration level via the 
dermal delivery route [71-75], inducing a call for continued research and 
development thereof. There are a number of reviews written that discuss these 
types of drug delivery systems [17, 68, 76, 77]. 
 
Liposomes are the most frequently used of the ones mentioned and a lot of 
research concerns this formulation. It is often made of phospholipid bilayers 
shaped as closed spherical shells with a hydrophilic center where 
pharmaceuticals can be kept during drug delivery and storage. The liposomes 
are being developed to suit a wide variety of drug delivery pathways, with 
more or less efficient results. 
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An example of a type of liposome that has received a lot of attention is the so-
called transfersomes. Transfersomes have a high elasticity and can endure 
deformation [78-82]. The patent holders claim that the flexibility of the 
particles makes them superior to other nano-particulate formulations. The 
transfersomes have been claimed to move deeper into the partly hydrated skin 
layers than similar vesicles [78]. However, it has been considered unlikely that 
the vesicles stay intact during transdermal drug delivery. It was recently shown 
that they do rupture [83], though a depot effect in the upper skin layers may be 
possible [17]. Examples of what these vesicles have been tested for are malaria 
treatment [84], cancer treatment [85], and as vaccine delivery vehicles [86], 
with varied results. 
2.3.2.3. PENETRATION ENHANCEMENT 
Most dermal delivery formulations and patches include penetration enhancers. 
There are a number of possible different ones to use. Many of these enhancers 
disrupt the intercellular lipid matrix of SC, either by increasing the fluidity and 
thus facilitating diffusion of the drug or by forming alternate areas within the 
bilayer structure [87]. The penetration enhancers should be non-toxic and non-
irritating, as well as without any pharmacological activity in itself. They should 
work rapidly and in a predictable way, as well as being a shield against loss of 
endogenous material while delivering the drug. When it is removed from the 
skin the barrier properties should rapidly return to the original structure. 
 
No perfect enhancer has yet been discovered but some fulfill more of these 
criterion than others. Examples of enhancers or groups of enhancers are water, 
sulphoxides and similar chemicals, azone, pyrrolidones, fatty acids, alcohols, 
fatty alcohols and glycols, surfactants, urea, essential oils, terpenes and 
terpenoids, phospholipids, and solvents at high concentrations [88]. 
 
Three different penetration enhancers (not counting water) have been included 
in our studies: propylene glycol (PG), pentane-1,5-diol (POL), and N-Methyl-
2-pyrrolidone (NMP) (molecular structures are shown in Figure 7). Depending 
on the use of the substances, which here are mentioned as penetration 
enhancers, different epithets can be used to present them. 
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Diols, such as PG and POL, are generally used 
as solvents or as anti-freezing agents but some 
have also been utilized as vehicles in 
pharmaceutical preparations [37, 89-92]. PG is 
the only diol widely used in dermatology [37, 
91], as it reduces the drug – tissue binding and 
has keratolytic properties, thus promoting 
permeation of the drug [49, 87, 93]. 
 
 
 
Figure 7 Molecular structure of PG, POL and NMP from top down. 
 
POL is not commonly used in pharmaceuticals, although it has been shown to 
be cosmetically acceptable and presents little risk for toxicity or skin and eye 
irritation relative to other diols [94, 95]. It is also an effective solvent, 
enhancer, water binding substance, antimicrobial agent, and preservative [91, 
95] and may therefore replace several ingredients in a skin composition. Today, 
POL is mainly used as a plasticizer in cellulose products and adhesives, in 
dental composites and in brake fluid compositions, and as a preservative for 
grain [90]. However, in recent years POL has been investigated as a dermal 
delivery enhancer with positive results (paper I, [95]) and can be used in 
dermal formulations. 
 
NMP is a somewhat questioned solvent used pharmaceutically to solubilize 
drug substances [96] and when studying in situ implant systems [97]. There 
have been uncertainties whether NMP causes irritations of the upper airways 
and eyes. A recent study of the chemosensory effects of NMP in human males 
found no evidence that this was the case [97]. Industrial uses include polyvinyl 
pyrrolidone production and use as a paint remover. 
2.3.2.4. OCCLUSION 
Another way of increasing the delivery is to apply an occlusive dressing 
covering the treated area. For example, in paper I the treated mice were covered 
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with impermeable plastic film over the area applied with formulation. 
Occlusion decreases the water gradient across SC, not allowing the water 
migrating out to leave the skin surface. Thus, the hydration of the outermost 
skin layers increase and dermal drug delivery is facilitated. 
 
According to Björklund et al. [46], the skin barrier can be temporarily opened 
by controlling the water gradient across the skin; the hydration of the skin can 
rearrange the structure within the SC lipid matrix as the structure depends on 
the surroundings [98]. In this way the concentration gradient can induce a 
change in the barrier properties causing phase changes and thus affecting the 
transport into the skin, that is the chemical potential can drive the diffusion 
motion [34, 99]. Moreover, increasing both the hydration and temperature of 
the membrane induces lipid mobility and results in increased amount of fluid 
state lipids, enhancing permeability further [30, 31, 34]. These alterations in 
lipid organization and barrier properties are also influenced by the skin pH 
gradient. The inside of our body consists of neutral pH while the skin surface is 
acidic, providing additional protection from permeation [100]. 
2.3.2.5. DIFFUSION 
For all non-mechanical delivery methods the delivery capacity of the 
formulation depends on the affinity for the SC environment for formulation and 
drug, and of the concentration gradient. The formulations and drug can be 
altered to enhance the partition into SC to some extent with the aid of solvents 
as previously discussed. However, further transport depends on the 
concentration gradient, in other words the passive diffusion, which is the rate-
limiting step. Fick’s law (equation 1) can also be used to calculate the diffusion 
parameters in these systems. The law states that the rate of diffusion across a 
membrane is inversely related to the thickness of the membrane and directly 
proportional to the concentration gradient of the substance on the two sides of 
the membrane. 
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where m is the cumulative mass of diffusing drug, t is the time, A the area 
applied with formulation, K the partition coefficient of the API between 
formulation and skin, D the diffusion coefficient of the API in the membrane, 
C0 the constant concentration of drug in the formulation (i.e., the amount of 
API is so much higher in the formulation compared to the diffusing amount that 
it can be considered constant), and h the thickness of the skin. For skin and 
other complex biological membranes it can be difficult to separate D and K. In 
such cases the permeability coefficient (P) may be more useful (see equation 2) 
 
ܲ ൌ ܭܦ         (2) 
 
[1] 
 
Calculating the diffusion parameters can be a good way to, for example 
compare the delivery capacity of different formulations, the SC affinity of 
different drugs, or to compare different membranes (e.g. animal, human, and 
artificial skin).  
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LIQUID CRYSTALLINE PHASES IN DERMAL DRUG 
DELIVERY 
3.1. LIQUID CRYSTALLINE PHASES 
Lipids and other amphiphilic molecules self-assemble [101, 102] into 
compositions of various kinds of micellar structures or phases in an aqueous 
environment when they reach a certain critical micellization concentration 
[103]. At higher concentrations liquid crystals are formed by polar lipids, such 
as GMO or GME, and water, where both components diffuse freely [104]. 
What structure is formed depends on the polar/non-polar shape of the lipid, and 
on the amount of water present. Water hydrates the polar head groups of the 
molecules through hydrogen bonding while the tails uses van der Waals forces 
to stay together [105]. 
 
Depicted in Figure 8 is a three component phase diagram. Each point in this 
diagram represents a certain weight percentage of the three components. A vial 
containing such a mixture may show one, two, or three phases (see further 
Chapter 4.1.). The one-phase areas that can be formed are marked in the figure. 
Those are hexagonal (H2), lamellar (Lα), cubic (I2), sponge (L3) and liquid (L) 
(see Figure 8), though the so-called sponge and liquid phases are not liquid 
crystals. Additionally, reversed forms of the hexagonal and cubic phases can 
form. These exist when the polar head groups face towards the enclosed water. 
In the phase diagrams, published within the scope of this thesis, the reversed 
forms are present (paper II). The transition between phases is driven by either 
enthalpy or entropy [106, 107]. 
 
The hexagonal phase consists of lipid tubes with water within or around, 
depending if it is a reversed structure or not. Lipid bilayer sheets with water 
between them define the lamellar phase. The sponge phase is not a true liquid 
crystalline phase but is best described as a swelled, melted cubic phase. The 
cubic phase is quite complex and consists of a ~3-4 nm thick lipid bilayer 
continuum traversed by two independent water channel networks of 
3
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approximately 5 nm diameter [108-111]. Adding to this, there can be different 
space groups formed within the cubic phase area based on minimal surfaces. In 
these systems the gyroid (g), diamond (d) and Schwartz’s Primitive surface (p) 
can form. The two which can form in the systems included in this thesis, d and 
g, are shown in Figure 8. 
 
 
Figure 8 The GME-POL-water phase diagram and examples of liquid crystalline phase 
structures. Letters denotes: liquid phase, L; lamellar phase, Lα; reversed hexagonal phase, H2; 
cubic phase, I2; and sponge phase, L3. 
 
The cubic phases, which are the main focus in this thesis, were discovered in 
the early 1960s by three groups independently [112-114]. Much were still to be 
clarified though and a decade later, with the use of nuclear magnetic resonance 
(NMR) and small angle X-ray diffraction (SAXD), new results were combined 
with the old so that the true structure of the cubic phase could be identified (for 
a comprehensive review see [115]). 
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The cubic phase structure provides some interesting and noteworthy properties 
that come in handy for many applications, as we shall see later: (i) it forms 
spontaneously, (ii) has a gel like texture, and (iii) has a high lipid bilayer/water 
interfacial area of ~400-600 m2/g lipid [108, 110, 116]. 
 
Sometimes a solvent, aprotic preferably, is needed for certain phases to form 
[101, 117, 118]. Depending on how effective the solvating capacity of the 
solvent is, the phases can be formed from a narrow or wide range of component 
ratios and the phase diagrams alter accordingly. 
3.1.1. LIQUID CRYSTALLINE PHASES IN NATURE 
In nature, lipid bilayers (and liquid crystalline phases) are found in abundance, 
as it is present in every cell. Focusing merely on cubic structures, important 
examples in nature are: the golgi apparatus, the endoplasmic reticulum, 
infolding of plasma membranes, and mitochondrial membranes during 
inactivity [103, 119, 120]. The lipid processes and phase shifting are believed 
to be very important for the cells. Signal transduction and inter- and intra-
cellular trafficking may be governed by lateral segregation of lipids and 
switching between phases [103, 119-123]. 
 
Moreover, lipid crystalline structures have been found within the lipid matrix 
of the skin [31, 124]. The lipids in SC are uncharged and relatively non-polar, 
contrary to the lipids forming the flexible liquid crystalline phases. 
Nonetheless, the liquid crystalline phases are very similar to the lipid matrix in 
SC [125]. The natural occurrence of the liquid crystalline phases and the shown 
efficiency when used as drug delivery vehicles makes it an interesting 
formulation to use for topical, and other, applications. 
3.1.2. COMPOSING THE LIQUID CRYSTALLINE FORMULATIONS 
It is possible to form the liquid crystalline phases from a number of lipids, with 
or without solvent, in the presence of water. In the scope of this thesis, 
however, the materials of interest for forming the cubic phases are the polar 
lipids, glyceryl monooleate (GMO), and glyceryl monooleyl ether (GME) 
together with water, and sometimes an aprotic solvent, PG, POL or NMP (for 
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details see paper II). GMO has been widely used in studies of these systems. It 
is derived through esterification of oleic acid, glycerol or refined vegetable oils 
[126] but are also formed endogenously in small amounts in the intestine 
during oil digestion [127]. GME (or selachyl alcohol) is the ether analogue of 
GMO and is found in nature in, shark-liver oil, for example. This lipid has 
several medical effects such as antibacterial and antifungal, as well as being an 
immunological stimulus [128]. 
 
 
Figure 9 Molecular structures of GME (top) and GMO (bottom). 
 
The molecular structures of GME and GMO are very similar, as illustrated in 
Figure 9. The carbonyl oxygen differentiates the lipids, which alters the phase 
behavior when in excess water: GMO forms a cubic phase and GME a reversed 
hexagonal phase [117, 129]. Aprotic solvents such as PG, POL or NMP, when 
mixed with GME and water, are able to transform the reversed hexagonal phase 
into a cubic phase [117] (paper II). The addition of the solvent has other 
positive effects on the formulation since it increases the water swelling capacity 
considerably, which in turn decreases the viscosity and makes the formulation 
easier to handle. Additionally, it is possible to form a cubic structure within 
minutes using GME, which was discovered by our research group and is of 
importance from a drug delivery point of view (see Chapter 3.3.2. and paper 
III-IV). 
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RELATED FACTS BOX 
WHAT DO CUBIC PHASES AND OUTER SPACE HAVE IN COMMON? 
 
Polar lipids and water molecules arrange themselves so that every molecule is 
as comfortable as possible with its surroundings. That is why the mixture in the 
formulations, given time, self-assembles into the cubic structure. At that point 
the system is in its most favorable state in terms of energy. This also leads to 
the formation of so-called minimal surfaces, in other words an area of average 
zero curvature. One example of such an area is a saddle point. Look at the red 
lines in Figure 10. Where the lines meet, the saddle goes up in two directions 
and down in two, that is it is neither a top nor a bottom. If you look at the cubic 
structure next to it you can see similar surfaces there. 
 
Figure 10 An example of a saddle point to the left, and a cubic phase structure to the right. 
After considering the cubic structure in nature, it is interesting to take an even 
bigger step back to see the whole picture. The minimal surfaces in my gel-like 
goo can in fact be found in outer space (Figure 11)! Mathematicians and 
theoretical physicists use them in calculations regarding, for example, black 
holes and in string theory. For the theoretical physicist, strings is another name 
for minimal surfaces [130, 131]. 
 
Figure 11 Minimal surfaces is the link between cubic structures and black holes. 
The same basic principles can be found everywhere in our universe. We just 
have to broaden our horizon to see it.    
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3.2. ACTIVE SUBSTANCES IN LIQUID CRYSTALLINE PHASES 
Liquid crystalline phases have the ability to dissolve/disperse hydrophobic, 
hydrophilic and amphiphilic compounds. The cubic phase, and the reversed 
hexagonal phase, has gained a lot of interest as a drug delivery vehicle and has 
been tried for oral, buccal, transdermal, vaginal, nasal, and intramuscular, 
administration [61, 132-137], for example. Examples of what has been 
incorporated within the different phases so far are small molecular APIs, 
proteins, peptides, vitamins, and DNA [61, 64, 109, 111, 138-148]. In our 
research, we used small molecules, proteins and additionally nano-particles 
(papers III-IV and Chapter 5.3.-5.5.). 
 
Adding these substances to the liquid crystalline formulation can of course 
affect the structure and phase behavior [139, 141-144, 149, 150] but it does not 
necessarily mean that alterations will take place [139, 151]. Knowing the phase 
behavior of the system at hand and preparing for potential changes due to the 
addition of molecules provides a dynamic drug delivery tool. 
 
Large bio-molecules in cubic phases have, to my knowledge, been studied for 
over 40 years since Gulik-Krzywicki et al. [152] was first with their 
phosphatidylinositol-lyosozyme-H2O system. Such bulky structures cannot be 
confined solely within the aqueous channels or the lipid bilayer but might be 
encapsulated in pockets or be partially in both water and lipid, thus possibly 
altering parts of the structure without destabilizing it [111, 153]. The active 
substance itself could also be affected in terms of solubility [154] and drug 
release. For example, something as big as DNA molecules cannot within 
reasonable time limits diffuse out of the cubic network [141]. 
 
Proteins incorporated in the cubic phase do not seem to undergo significant 
structural changes [139, 141]. Thus, the cubic phase shows an ability to protect 
the proteins within from degradation and prolong their half-life [104, 108, 155]. 
One reason for this is that the activity of water in the channel systems is 
reduced [108, 156] resulting in protection of proteins and peptides [157]. These 
facts have been put to use in, for instance, membrane protein crystallization 
[158]. 
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There are a number of reviews that discuss different aspects of the areas 
mentioned above [70, 103, 108, 109, 153, 159] and Rizwan et al. [159] show a 
list of compounds of different molecular size that have been incorporated into 
the cubic phase. A rough size evaluation of such compounds is summarized in 
Figure 12. 
 
 
Figure 12 Approximate size ranges of various substances incorporated into the cubic phase. 
 
One advantage of using liquid crystalline phases as a drug delivery vehicle is 
the ability to achieve sustained release. Many studies of sustained release from 
the cubic phase have been performed [108, 109, 141, 142, 145, 157, 160-164], 
showing release of the APIs that follows the square root of time according to 
Higuchi [165, 166]. 
 
The formulation can be modified to some extent in order to allow for a faster or 
slower diffusion of the API. Altering the diameter of the water channels is one 
very direct way to modulate the release [141]. Examples of ways to do such 
modulations include using different charged lipids and surfactants [167, 168]. 
The viscosity of the system is another factor that seems to have an effect on the 
release rate; the higher the viscosity the slower the release [164, 169]. 
Additionally, the continuous nature of the lipid bilayers provides the possibility 
for vast migration. Investigations of the migration of oligonucleotide within the 
cubic phase compared to the migration in a hydrogel showed this property to be 
of importance [170]. 
 
It is possible to shift phases from one to another by changing, for example, 
amount of water, temperature and pressure. This can be used for drug release 
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purposes if the phase shifting occurs under controlled circumstances. During 
the transformation between two phases caution must be observed as drug 
release may increase temporarily [162]. The spontaneous formation of a cubic 
phase, when in a more water rich environment, from a lamellar starting point is 
one example [109, 171, 172]. The researchers investigated this idea with the 
hope of commercialization. However, the researchers soon realized that there 
was a risk of burst release [171], and the idea had to be revised to find a 
functioning approach to the same solution [173, 174]. Going from a cubic to a 
reversed hexagonal liquid crystalline structure can be a way of suppressing 
drug release [147]. There are examples of using pressure or, even better, 
temperature to achieve such a shift [147, 175, 176]. 
3.3. CUBIC PHASE FOR DERMAL DRUG DELIVERY 
Depending on the intended delivery route, the cubic phases have more or less 
attractive features. The highly viscous phase might be suitable for oral delivery 
[126, 135, 162]. It is also mucoadhesive with the ability to stick to the skin 
surface [60, 61, 70, 132, 133]. However, to some extent it is a question of taste 
as some researchers find the high viscosity an advantage in dermal delivery 
[61, 62] while another finds it to be a disadvantage and prefers the less viscous 
sponge phase [177]. 
 
Liquid crystalline phases and the cubic phase in particular have shown to be 
good candidates for transdermal drug delivery (paper III-IV) [61, 62, 64-67]. 
The reasons for this are numerous: it has, as mentioned, adhesive features, it 
can be engineered to provide sustained delivery, it is non-toxic, and it can 
contain a wide variety of active substances [60-63]. Moreover, because of the 
skin construction any vesicle able to penetrate must be deformable and fluid in 
the lipid bilayers [68]. Delivery vehicle interaction with the skin lipids can 
influence a phase change so that more of the solid lipid sections of the 
intercellular matrix become fluid, thus enabling enhanced molecular diffusion 
[69]. 
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3.3.1. THE CUBIC PHASE IMPROVING DERMAL DRUG DELIVERY 
There are examples of studies using cubic phase systems as a transdermal drug 
delivery vehicle for treating both dermal diseases and internal problems where 
systemic delivery is needed. With the aim of treating atopic dermatitis, GMO-
based formulations were studied on excised rat skin resulting in effective skin 
delivery [178]. In another study enhanced systemic effect was observed both in 
vivo and ex vivo when using a cubic formulation compared to two 
microemulsion gels [179]. Yet another study showed that the cubic phase were 
more efficient for transdermal drug delivery than the reversed hexagonal and 
lamellar phases [180]. However, it must be pointed out that some of these 
results were obtained from studies performed on shaved rats. The shaving 
disturbs and affects the skin resulting in a less than optimal set-up. However, 
the dermal delivery studies included in this thesis (papers III-IV) concur with 
the observation that the cubic phase increases the extent of drug diffusion. 
 
A relevant example of improving dermal drug delivery by using the cubic 
phase is within the skin cancer treatment termed photo dynamic therapy (PDT) 
([61], paper III). In short, this treatment is based on making cells sensitive to 
light so that when illuminated the cells die. The use of δ-aminolevulinic acid 
(ALA) and ALA-esters in PDT is the object of many studies even though the 
more specific area of interest can differ from cancer treatment to reducing acne, 
for example. There are examples of clinical studies reporting positive effects 
when using methyl aminolevulinate (MAL) in PDT treatment compared to 
other methods such as surgery and cryosurgery [181, 182]. Experiments of the 
permeation of ALA across skin [183, 184] and the stability of the drug in 
formulated drug delivery vehicles [61] have also been studied in detail. Studies 
using different drug delivery vehicles arrive at different conclusions with 
regards to the transdermal absorption of ALA and MAL. When comparing the 
results presented in these references with the results obtained in our study 
(paper III) it is evident that the cubic formulations we present have a 
significantly enhancing effect on absorption of the drug. 
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3.3.2. THE ON DEMAND CUBIC FORMULATION 
A protocol for “on demand” preparation of cubic formulations suitable for 
dermal drug delivery was developed, building on previous work within the 
research group. The cubic formulations previously used needed to be allowed 
to equilibrate at least over night before use. The new protocol is especially 
suitable for drugs that have limited stability in solution, and therefore should be 
prepared as close to the administration occasion as possible. Thus, it was 
evaluated in the aforementioned in vivo PDT study (paper III). 
 
The preparation of the formulation includes one syringe filled with GME and 
solvent, and one syringe containing water. The syringes are joined with a 
connector that holds the API in dry form. By using the syringe pistons to push 
the content back and forth through the connector until thoroughly mixed, the 
cubic phase formulation is produced in less than one minute (see Figure 13). 
 
 
Figure 13 The mixing of components to obtain an on demand cubic formulation. 
 
This formulation solves the stability issue of the API stored in the connector 
piece. Moreover, by merely using GME instead of GMO it circumvents the 
stability issues otherwise present in a standard GMO-based cubic formulation 
due to hydrolysis of the extra carbonyl oxygen. The solvents used to prepare 
the on demand cubic phase were PG and POL, but other solvents could also be 
used. 
 
As the formulation proved to be an effective delivery vehicle for small 
molecules, it was also tested for proteins and nano-particles (NP) (BSA, gold 
nano-particles (AuNP), and quantum dots (QD)), discussed further in paper IV 
and in Chapter 5.4.-5.5.) with positive results. This on demand formulation is a 
vital part of the research presented in this thesis. 
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3.4. THE HYPOTHESIS: INTERACTION BETWEEN FORMULATION AND SKIN 
When working with the cubic formulations as a dermal drug delivery vehicle 
one thing is abundantly clear: the phase is virtually impossible to wash of. This 
has to do with the fact that it swells in water to a certain extent. However, it is 
also due to an interaction with the skin that is not completely explained as of 
yet. Through the use of different techniques and methods (Chapter 4) further 
information could be gathered about the formulations and their skin 
penetration, as well as dermal drug delivery abilities (results in Chapter 5). 
Combining these results with information about the lipid matrix (Chapter 
2.2.1.) and the phase behavior of the system (paper II and Chapter 5.2.) makes 
it possible to hypothesize over what happens when we add the formulation to 
the skin surface. 
 
The formulations applied to the skin samples in the included studies were the 
GMO-water based and the GME-water-solvent based cubic phases. These 
molecules and formulations are very similar but the systems differ in a few key 
points. In excess water GMO forms a cubic phase while GME forms a reversed 
hexagonal phase and needs the solvent to form a cubic phase. In the dermal 
delivery studies no significant difference could be seen when small molecules 
were tested; however, for large molecules and nanoparticles the only efficient 
delivery vehicle was the GME-water-solvent based cubic formulation. The 
change of lipid, decided on due to possible commercialization reasons, proved 
to be an interesting choice. 
 
The applied formulation provides hydration to the tissue, both from the 
formulation itself and through occlusion of the area. The hydration results in 
swelling of the cells and straightening of the lipid matrix [15]. The samples 
treated with the cubic formulation swell more than water treated samples. This 
is not unlikely as the lipids in SC are uncharged and relatively nonpolar, thus 
less prone to swelling in a hydrating environment compared to the polar lipids 
of the cubic formulation [15, 185]. However, the liquid crystalline phases are 
similar to the lipid matrix in SC [125]. Introducing the formulation to the skin 
lipid layers should thus induce an increased swelling of the tissue due to 
increased uptake of water. Moreover, the high relative humidity at the 
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boundary between phase and skin will result in increased membrane 
permeability [34]. Adding to this is the fact that the solvent/penetration 
enhancer included in the GME-based formulation has keratolytic properties 
[49, 93, 186]; therefore, the following hypothesis may be a plausible 
explanation to the increased delivery: 
 
The applied GME-based cubic formulation adheres to the surface, occludes and 
hydrates the skin. When the cubic phase comes in contact with the water 
present within the skin the solvent is released. The hydration from occlusion in 
combination with the released solvent generates swelling of the cells and 
detachment from each other. When the cubic phase loses POL it will transition 
into a reversed hexagonal phase, in other words it goes from a continuous to a 
discrete system, according to the phase diagram in paper II. The influenced 
skin lipid matrix meets the reversed cylindrical micelles budding of the applied 
formulation, enabling migration between the cell layers. The release of the 
solvent continues during the skin penetration, as water will always be present. 
 
 
Figure 14 An illustration representing the GME cubic phase from which a reversed cylindrical 
micelle emerges, represented by a snake, preceded by its cloven POL tongue and carrying the 
loaded API as a swallowed prey. 
 
Moreover, the fluid lipids of the formulation come in contact with the lipids of 
the quite rigid matrix and increase the mobility of the lipids therein, possibly 
altering the local liquid crystalline structure. This combination of events work 
its way downward, opening pathways and dragging with it what was first 
loaded into the cubic phase. This process takes time and droplet-like depots can 
form (see Chapter 5.5.) from where the progression continues. Smaller 
molecules may be delivered into the cells from the depots while larger 
molecules and particles most likely follow the formulation until deposited. 
-35- 
 
RELATED FACTS BOX – ANCIENT SKIN CARE 
 
Today skin care and cleanliness is a given, but also lucrative business. This has 
not always been the case. In the cold northern countries washing and skin care 
was not high priority, though it was never as bad as during the middle ages 
when bathing was more or less unheard of. Women could possibly rinse their 
skin with wine to get a smooth, silky touch. Other than that, Europeans in 
general used perfume to cover the body odors instead of washing [187, 188]. 
 
The situation further south was quite different, where both culture and religion 
requested cleanliness. For example, documents from Egypt, Greece, and 
Roman lands, as well as the Bible as historical documentation from the same 
time period, describes washing 
procedures and lubrication with oils as a 
daily ritual in many cases. Cleopatra is 
well-known for bathing in sour milk to 
stay young. The lactic acid is favorable 
for skin exfoliation, so why not give it a 
try? The Bible also mentions milk baths, 
as well as both men and women putting 
oil on their faces and hair. The most common choice was olive oil, which 
sometimes was infused with herbs or flowers and sometimes in combination 
with honey as a further moisturizer [187-189]. 
 
The combination honey and oil was also commonly used by men and women in 
Greece for health and looks. The athletes in ancient Greece covered their 
bodies with olive oil and fine sand to regulate body temperature and for 
protection from sunburns [187, 188].  
 
 
We should learn from these ancient ideas and take good care of the skin; it is 
our largest organ and must last a lifetime. Watch out though! The etheric oils 
which were frequently used are now known contact allergens, and many a vain 
lady succumbed to arsenic or led poisoning which were common ingredients in 
cosmetic products. We can all be thankful for lifesaving research results!☺ 
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RESEARCH METHODS AND ANALYSIS 
Over the years of work leading up to this thesis a large number of 
techniques were used. These techniques will be described briefly and, to some 
extent, compared to other possible techniques that were disregarded from use 
for different reasons. For further details of the methods and equipment used, 
readers are referred to the included papers. All techniques were chosen in the 
attempt to find the best way to answer our various questions. 
4.1. ANALYZING LIQUID CRYSTALLINE PHASES 
The most common techniques used to analyze liquid crystalline phases are 
crossed polarizers, SAXD and NMR. The combination of these techniques 
gives a clear image of the phases and phase behavior. Thus, they are valuable 
tools when constructing a phase diagram. For a complete phase diagram, a vast 
number of samples have to be prepared, analyzed, and composed. The 
mentioned methods have been used for sample analysis in the papers included 
in this thesis and will all be presented here. 
4.1.1. CROSSED POLARIZERS 
Crossed polarizers (Figure 15) are very useful for determining if there is 
birefringence in the liquid crystalline samples. After ocularly determining the 
number of phases present in the vial and the relative amount of each phase, it is 
possible to obtain a first indication of which phase is which and its position in 
the vial by holding the sample between crossed polarizers. Both lamellar and 
reversed hexagonal phases alter the direction of the light making the sample 
look like it is glowing (anisotropic phases). Cubic, sponge and liquid phases do 
not glow, thus looking completely black (isotropic phases). 
 
4
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Figure 15 Schematic image of crossed polarizers where the light is blocked in all but one 
direction, thus if one of the plates is turned 90° no light will pass through. 
 
For more detailed information about the texture of the birefringent phases or of 
phase shifts due to, for example, temperature alterations, an optical microscope 
equipped with crossed polarizers can be used. A cubic sample can, for instance, 
be studied under the microscope and stepwise heated until it turns into a 
reversed hexagonal phase. This gives an indication of the heat tolerance of the 
phase (studied in paper II). The reversed hexagonal phase can be distinguished 
from the lamellar phase, as they show a colorful image and a black and white 
structure, respectively. Any further details must be found using other 
techniques. 
4.1.2. SMALL ANGLE X-RAY DIFFRACTION 
The small angle X-ray diffraction (SAXD) technique is applied to study 
structures that are approximately 1-100 nm in size. An X-ray photon primary 
beam is directed at the sample at a small angle causing photons to be emitted in 
all directions as scatter. The photons can sum up and give rise to diffraction. 
Diffraction is obtained when the difference in distance between the planes in 
the sample are equal to the wavelength of the radiation, stipulated by Bragg’s 
law (equation 3). Only the diffracted photons that travel parallel to a specified 
direction are allowed into the detector which is divided into 1024 channels, in 
other words angles or scattering vectors [190]. 
 
When data is collected Bragg’s law [191] is used to calculate the distance 
between layers within the sample. 
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nλ = 2d sin θ       (3) 
 
where n is an integer, λ is the wavelength of the incoming beam, d the distance 
between two molecular layers, and θ the angle between incoming or reflected 
beams and the molecular layer (see Figure 16). This equation shows that for a 
small d, such as within a molecular or atomic lattice, the incoming primary 
beam angle must be wide. For a larger d, such as in the liquid crystalline 
phases, the angle must be small in which case SAXD is the suitable technique 
to use [190]. 
 
 
Figure 16 Schematic image of Bragg diffraction, where two beams of identical wavelengths hit a 
surface and are reflected by atoms in two different planes. The lower beam travels a distance of 
2dsinθ. Constructive interference occurs when this length corresponds to an integer multiplied by 
the wavelength of the beam. 
 
To calculate the distance between the planes, d, from the SAXD measurements 
equation 4 is used. 
 
d = 2π/q        (4) 
 
where q is the scattering vector obtained during measurements. In this way 
information such as bilayer structure and thickness of the sample can be 
obtained [190, 192, 193]. The diffraction pattern and q position of the obtained 
spectra gives the sample space group and (nano)size, respectively. 
4.1.3. NUCLEAR MAGNETIC RESONANCE 
NMR is a versatile analytical technique used in many disciplines of scientific 
research, medicine, and various industries, for example, for determining the 
content and purity of a sample and its molecular structure. It can be used to 
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quantitatively analyze known mixtures or solve the basic structure of unknown 
compounds. NMR can further be used to study solubility, diffusion, phase 
changes, and other physical properties on a molecular level. To achieve all of 
these applications a number of different NMR techniques have been developed 
[192]. 
 
To describe NMR in its most basic terms, I cite Joseph P. Hornak: “Nuclear 
magnetic resonance is a phenomenon which occurs when the nuclei of certain 
atoms are immersed in a static magnetic field and exposed to a second 
oscillating magnetic field. Some nuclei experience this phenomenon, and others 
do not, dependent upon whether they possess the property called spin.” [194] 
 
Accordingly, these electrically charged nuclei may transfer energy between 
energy levels when the external magnetic field is applied. When the spin 
returns to its base level the obtained energy is emitted at the same frequency as 
was sent in. The transfer signal is measured and processed, yielding an NMR 
spectrum for each such nucleus [194]. 
 
Different nuclei, even within the same molecule, come into resonance at 
different frequencies. This can be used to provide information about the 
molecular structure and position of the different parts of the molecules in the 
media. The so-called chemical shift shows the difference between the 
resonance frequency of each nuclei and a reference standard [192, 194]. This 
was used in our work (paper II) where the obtained single 1H resonances from 
the ,  and  hydrogen’s of POL provided chemical shifts in lipid and water 
domains of the cubic and sponge phases. From these results the distribution of 
the POL molecules in its surroundings was determined. Moreover, the 2H NMR 
signal pattern of some phases was recorded to confirm the presence of a sponge 
phase in the GME-POL-W phase diagram. The 2H NMR signal originates from 
deuterated samples, in this case water replaced with D2O. 
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4.2. MODEL SYSTEMS 
The techniques presented below were used in vivo or in vitro/ex vivo. The in 
vivo methods were executed using hairless mice in search of a pharmacological 
response. In vitro/ex vivo measurements were performed on excised human 
skin tissue in order to screen a number of formulations and diffusing molecules 
and particles. 
4.2.1. IN VITRO AND EX VIVO: DIFFUSION CELLS 
Franz cells are very common equipment to use for penetration studies through 
human or animal skin, artificially grown skin, or other membranes. The simple 
layout is presented in Figure 17 with the skin sandwiched between the 
formulation and the receptor fluid, allowing for a set-up as similar as possible 
to the in vivo situation with regard to temperature and so on (it is also possible 
to use these cells for iontophoresis, for example). This technique was used for 
the majority of samples within the research presented here. No other in vitro/ex 
vivo method can, to my knowledge, mimic the natural dermal application 
situation better.  
 
However, some may argue that techniques such as tape stripping, which can be 
used directly on the patient, are preferable. In tape stripping a tape adheres to 
the skin surface and is then pulled off, taking some of the skin layers with it. 
This is not too painful and such multiple procedures can be performed before 
the area is too damp for the tape to adhere. Each sample can then be analyzed 
in search of, for example, the amount of API. However, this method has a 
number of inherent difficulties such as: i) by disrupting the layers artifacts can 
be introduced, thus it is not possible to remove specific homogenous layers 
making the location in the skin somewhat uncertain [195]; ii) the test subject is 
subjected to the drug with the possibility of unwanted systemic effect; and iii) 
the tissue must be clean and dry before the technique can be used. The latter 
would create obstacles in our case, as the cubic formulations are hard to 
remove without leaving an oily residue. 
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Figure 17 A Franz diffusion cell with donor chamber, receptor chamber and clamp, seen in the 
top image. The receptor chamber is filled with fluid and the skin sample is placed over the 
opening with the surface facing upward. The donor chamber is placed on top of the skin and the 
whole diffusion cell is clamped together, enabling penetration studies of the substance applied to 
the skin via the donor chamber. 
 
The skin was treated with the formulations in the diffusion cells before they 
were analyzed using different methods depending on the research question. The 
diffusion always had to be monitored, and thus there was a need to investigate 
the amount API present in the receptor fluid and to enable looking deep into the 
skin tissue. 
4.2.2. IN VIVO: TRIALS FOR PHARMACOLOGICAL RESPONSE 
In order for an API to reach the market it must go through animal and human 
trials. Animal testing is a proof-of-concept method used for APIs and 
techniques prior to clinical trials. The desire is to do as little animal trials as 
possible and each study must have an ethical approval before the experiments 
can commence. Well known guideline principles for more ethical animal 
testing are the Three Rs: i) Replacement – whenever possible, replace animal 
trials with another method to achieve the same scientific aim; ii) Reduction – 
use as few animals as possible and/or obtain more information from the same 
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number of animals; and iii) Refinement – enhance animal welfare and 
minimize pain, suffering or distress for the animals used [196]. 
 
There are a number of different animal models to choose from that are more or 
less similar to humans. Pros and cons must be carefully weighed with regards 
to factors such as costs, housing opportunities, ease of handling, animal 
robustness, and immunological status. Mice are a common choice of animal 
that are easy to maintain and acquire at a relatively low cost. Mice are thus 
ideal to use when a high number of animals are needed for statistical 
assessment [197]. 
 
In the in vivo trials performed for paper III, hairless mice (see Figure 18) were 
chosen in order for us to be able to apply the formulation on intact, unshaven 
skin. The PDT process must be studied on living organisms in search of a 
pharmacological response. ALA enters the heme biosynthesis cycle, which 
only functions in living cells, thus the need for live animals in this case. For our 
need for statistical data, mice were a good choice. They are small animals that 
are easy to handle, have short life-cycles and the housing facilities have a vast 
experience of these creatures. 
 
 
Figure 18 Photographs of an anesthetized mouse during application of cubic formulation (to the 
left) and spectroscopic measurements performed on the mouse through the occluding dressing (to 
the right). 
 
For assessment we used a non-invasive method: fluorescence 
spectrophotometry (fluorescence will be further explained in Chapter 4.3.1.3.). 
An excitation wavelength appropriate for the PpIX signal was sent into the 
tissue and the emission was detected through a fiber optic coupler accessory. 
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Fluorescence readings were simply performed by holding the optical probe 
against the skin of the treated mice. This was the easiest way to detect the 
changes in PpIX formation over time without injuring the animals. 
4.3. ANALYTICAL METHODS 
4.3.1. LASER SCANNING MICROSCOPY 
When facing the problem of clear imaging deep into skin tissue without 
histopathological or other invasive preparations, a number of issues arise. 
Firstly, the skin scatters light, making a clear image hard to obtain. Red near-
infrared (NIR) light are spread the least, thus to achieve deep light penetration, 
wavelengths ranging from approximately 700-1000 nm are preferred. NIR light 
not only penetrates deeper into scattering tissue but is also generally less 
phototoxic [198]. Secondly, the skin consists of a number of layers with 
different structures. In order to visualize this, the technique used must be able 
to provide a detailed 3D view. 
 
Optical microscopy is commonly used with histopathological samples. 
However, the resolution and details of the obtained images are often 
insufficient. A better choice would be to use confocal microscopy. This 
fluorescence microscopy technique use linear (one-photon) absorption (see 
Figure 19) processes for contrast generation. It achieves 3D resolution and 
optical sectioning through the use of a detection pinhole that rejects all light 
that does not originate from the focus. Due to the scattering effect of the tissue 
this limits the use on the skin surface for high-resolution imaging. 
-45- 
Figure 19 Jablonski diagram showing energy levels for one-photon absorption (A), two-photon 
absorption (B) and coherent anti-Stokes Raman scattering (C). 
 
A further improvement of the microscopy technique was necessary in order to 
perform non-invasive imaging. To avoid the effects of scattering and to take 
advantage of the low absorbing near-infrared excitation light, a non-linear 
process was employed. One example of a non-linear process is multi-photon 
excitation. For such an unlikely process to occur at least two photons need to 
combine their energies to excite the fluorescent molecule simultaneously 
(within ~0.5 fs) (see Figure 19). The emission will occur in the visible spectral 
range, same as for one-photon excitation, but with the aid of pulsed lasers 
achieving high peak intensities the multi-photon excitation can take place using 
NIR light [198]. Moreover, the excitation only occurs at the focal point, hence 
the technique is more specific even without the use of a pinhole [199]. Two 
techniques that employ this are Two-photon microscopy and Coherent anti-
Stokes Raman spectroscopy, both presented below. 
4.3.1.1. TWO-PHOTON MICROSCOPY 
Two-photon excited fluorescence laser scanning microscopy (TPM) was used 
in paper IV for acquiring images deep within the light spreading skin tissue. As 
mentioned above, it makes use of low scattering, low absorbing NIR excitation 
light, and more effective emission detection compared to confocal microscopy. 
Moreover, the skin auto-fluorescence has an emission wavelength within the 
green area, which enables detection of added red fluorescing molecules or 
particles. This can be used so that the auto-fluorescence shows where in the 
skin layers the image is taken while the red fluorescence depicts the location of 
Ground state 
Virtual states 
Excited state 
A      B       C 
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the added substance. The auto-fluorescence originates from a number of 
different substances within the skin, which are presented in Table 3. Our work 
is based on the knowledge provided by a number of interesting studies and 
reviews that have been published on the use of two-photon microscopy on 
human skin in vivo and ex vivo [199-204]. 
 
Table 3 The location of auto-fluorescing substances found in skin tissue. 
Skin layer Source of auto-fluorescence 
SC Keratin 
SG NADPH 
SB Melanin 
Dermis Elastin, Collagen 
 
With the aid of TPM, diffusion of nanoparticles, as well as fluorescently 
labeled proteins, have been visualized in our studies. TPM is becoming more 
and more used for skin imaging due to it being an efficient tool when aiming 
for visualization of events taking place deep into light spreading tissue [38, 
205-207]. 
 
It is noteworthy that the auto-fluorescence signal in TPM increased when 
applying a cubic formulation to the skin sample. This may be due to optical 
clearing [208]. 
4.3.1.2. COHERENT ANTI-STOKES RAMAN SPECTROSCOPY 
Coherent anti-Stokes Raman spectroscopy (CARS) has its background in 
Raman spectroscopy, as the name suggests. In Raman spectroscopy the 
electrons are pumped by a single continuous wave to an imaginary energy state. 
A way of explaining this, perhaps a somewhat peculiar statement, is that the 
photons that are sent into the electron clouds influence the electrons without 
affecting them. When the electrons then return to a vibrational state the energy 
difference is detected. This can be a decrease in energy called Stokes, but it can 
also be an increase in energy called anti-Stokes. The latter is used in CARS. 
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The CARS process uses the fact that different chemical bonds have different 
vibrational spectra, much like a fingerprint [209, 210]. The CH bonds, which 
are present in a high amount in lipids and thus of interest in my research, are 
one example of such bonds. In order to see these fingerprints two laser pulses 
are needed, similar to TPM. The difference in frequency between the two 
pulses must be set to match the vibration of the molecule aimed to study. By 
using the two pulses, called pump and Stokes, the system can contain both the 
ground state and an excited state at the same time (see Figure 19). If the 
corresponding vibrational spectra is present in the sample this will result in the 
anti-Stokes signal [211]. 
 
CARS can be combined with other microscopy techniques, such as TPM, for 
obtaining an even more complete image of the tissue at hand [212]. In this way 
it is possible to selectively image biomolecules or other complex structures 
without any labeling. The CARS signal is detected on the blue side of the 
incoming radiation, which is free from fluorescence (compared to the Raman 
signal which is detected on the red side where it might have to compete with 
other fluorescent processes). 
4.3.1.3. FLUORESCENT SIGNAL 
In order for the TPM technique to be useful there must be a fluorescent signal 
in the sample. In a linear process the emitted fluorescent light has a longer 
wavelength than the absorbed light, though when the two-photon process is 
used the emission of radiation has a shorter wavelength than the absorbed 
radiation. 
Fluorophores 
A fluorophore is a fluorescent chemical compound (typically containing 
aromatic groups), that after excitation re-emits light. The fluorophore is excited 
by a light source and emits light when relaxing back to its ground state (in the 
same way as shown in Figure 19). As mentioned, the emitted fluorescence light 
has a longer wavelength than the absorbed light. This is due to a loss of energy, 
between excitation and emission, known as Stokes shift. Fluorophores are, for 
biological applications, ideally small molecules that can be linked to larger 
molecules, such as proteins, in order to study the complex. Pioneering work in 
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the context of TPM, studied 3D distributions of fluorescent probes in excised 
full-thickness human skin [33]. 
Semiconductor nanocrystals 
Quantum dots (QDs) are luminescent semiconductor nanocrystals. The 
mechanism behind the luminescence differs between fluorophores and QDs. As 
previously explained, fluorescence from molecules is due to the excited 
electrons that fall back into their ground state. However, in semiconductor 
nano-crystals the movements are a bit more restricted. When an electron in a 
semiconductor is excited from the valence band to the conduction band, a hole 
in the valence band is created. This electron hole pair is called an exciton, and 
can be compared to the state between the proton and the electron of the 
hydrogen atom. The size-related optical and electronic phenomena are also 
known as “quantum size effect”, hence the name Quantum dots [213]. 
 
QDs are characterized as having sharp and symmetrical emission spectra, broad 
absorption spectra, size dependent emission wavelength tuneability, high 
quantum yields, and good chemical stability and photo-stability [214]. The 
particle surface is often covered with an organic coating that is necessary 
during synthesis to control, for example, the growth, solubility and crystal 
morphology (Figure 20). Depending on application this can later be of use to 
couple other coatings to the particle [213], for instance to create stealth effect 
(see further Chapter 5.5.). 
 
 
 
Figure 20 Schematic image 
showing a possible structure of 
QDs, with a cadmium and 
Zink-based core covered with 
an amphiphilic polymer to 
which polyethylene glycol 
(PEG) is coupled in order to 
achieve stealth effect. 
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Plasmon resonance 
Gold nanoparticles (AuNPs) are somewhat more difficult than QDs and 
fluorophores to use in optical microscopy such as TPM. The effect, which 
enables visualization of AuNPs, is called surface plasmon resonance (SPR). 
The SPR in AuNPs is the coherent excitation of all the free electrons within the 
conduction band, leading to oscillation. The surface of the particle plays an 
important role for SPR through altering the polarizing conditions for the metal, 
which shifts the resonance to optical frequencies. Globular nanoparticles give 
fewer signals than nanorods, for example. Thus, the surface plasmon absorption 
is a small particle effect and not a quantum size effect [215]. What complicates 
the matter is that the spherical particles cannot be too far apart if they are to be 
detected using TPM. (This we learned the hard way.) 
 
AuNPs have been used in cell studies using TPM for assessment. The 
conclusion drawn by the authors, quite logically, was that if AuNPs were 
detected they were attached to or incorporated within the cells, and if they 
could not see any particles, there were none present [216]. As this seemed 
straight forward, our idea was to incorporate AuNPs in the formulations, apply 
them to the skin and study the penetration into skin tissue (in the same way as 
later was performed using QDs, see Chapter 5.5.). However, the 5, 20 or 40 nm 
spherical AuNPs were not detectable using TPM in water solution, the cubic 
phase, or the skin tissue. Only aggregates could be detected. This of course 
raised questions about the measurements. When drying AuNP solution on a 
glass slip it was clear that the obtained signal only originated from aggregates. 
The problems to obtain a two-photon signal lead to a more in depth study of the 
physical origin of the luminescence signal (work to be published) [217]. The 
results showed that for 10 nm particles the longest separating distance possible 
was <10 nm. These findings imply that particles can be present though too far 
apart to be detectable using TPM. 
 
In my opinion this is an important issue that can cause problems, for example, 
for cell studies such as those mentioned above. In our case it led to performing 
some initial experiments with SEM and TEM to detect the particles in the skin 
samples (ongoing work) and to replace the AuNP formulations with systems 
containing QDs in order to follow the diffusion using TPM. 
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4.3.2. CHEMICAL ANALYSIS 
4.3.2.1. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
HPLC (High Performance Liquid Chromatography) is a very commonly used 
technique for chemical analysis. HPLC can be used to separate, quantify and 
identify different compounds. A suitable mobile phase is pumped at a steady 
pace, pushing solubilized samples through an analytical column, resulting in 
separation of the components of the sample. The sample components elute at 
the other side of the column at different times depending on how much the 
composition of the column delays specific substances. This separation is 
affected by choice of column and composition of the mobile phase. Variations 
of the latter can include different solvents, pH, ion strength, and so on. During 
the first study performed (paper I), the amount of terbinafine was detected in 
receptor fluid samples. As terbinafine absorbs within the UV range it could be 
analyzed using a UV detector, where the eluted fractions continue through a 
flow cell and energy changes are detected. 
4.3.2.2. TECHNIQUES USED WITHIN PROTEOMICS 
The analysis of proteins and particles in skin tissue originates from the 
scientific question whether or not the cubic phases are able to enhance dermal 
delivery of large molecules and particles. Actual proteins can interact with both 
the formulation and the skin, thus the nanoparticles were chosen to be easily 
traced inert models of protein drugs. However, as the penetration of QDs into 
viable epidermis was successful, the diffusion of fluorescently marked BSA 
was also tested as a model of a bulky protein drug. 
 
The TPM results showed a deep penetration of BSA into ex vivo skin. With 
knowledge of dermal delivery of large molecules this was quite spectacular; 
therefore, we felt the need to make certain that the obtained signal originated 
solely from the TMR-BSA complex. Although unlikely, it might be possible 
that the fluorophore leaves the protein and is separately transferred deeper into 
the skin (TMR is covalently bound to BSA and it should thus take active 
cleaving to separate them), or that free TMR could be present in the sample 
despite the cleaning made by the suppliers. With this in mind, the need to find a 
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way to distinguish BSA from HSA in skin samples arose. Our work turned 
towards the scientific branch of Proteomics. 
 
Proteomics studies the structure and function of proteins. The word “proteome” 
is derived from PROTEins expressed by a genOME, and it refers to all the 
proteins produced by an organism, much like the genome is the entire set of 
genes. Proteomic technologies play an important role into finding the link 
between genes, proteins and disease. Often the findings make it possible to 
discover defective proteins that cause particular diseases, enabling the 
development of new drugs that either alter the shape of a defective protein or 
mimic a missing one [218]. 
 
Proteomics is a complex field with a number of available techniques depending 
on the research question. The techniques focus on revealing structure and 
conformation, as well as measuring protein concentrations in varying 
conditions. Within each step, for instance structural analysis, purification, 
protein concentration, and separation a number of techniques can be used. 
 
With the aid of experts in the field, the choice of techniques fell on 2D gel 
electrophoresis combined with LC-MS/MS analysis. This combination enables 
separation of the proteins on size and thereafter the ability to distinguish BSA 
from HSA. 
 
A few alternative methods were discussed but ruled out. One example is 
albumin depletion, which is normally used to remove serum albumin (SA) from 
blood samples, for example. The high amount of SA can disturb the analysis of 
low abundant proteins, thus enriching columns, and antibody-based methods 
have been developed to remove SA [219]. This method would in our case be 
used to single out the SAs and then distinguish BSA from HSA. However, 
compared to the approach we chose, this would be more costly reaching the 
same goal, and was thus ruled out. 
 
Another idea was to use immunoprecipitation. This technique uses a specific 
antibody that binds the particular protein searched for in order to isolate it from 
the other proteins in the sample. The protein is immobilized on solid substrates 
and later eluted and identified [220]. However, this is an extremely time 
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consuming procedure which can take up to half a year to perfect, as a specific 
antibody only working for BSA would have to be located for the technique to 
be usable. 
 
As the techniques chosen achieved the set goals, no other methods were tried. 
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RESULTS 
The research results included in this thesis are here summarized and 
further discussed. 
5.1. PAPER I 
EFFECT OF PENTANE-1,5-DIOL AND PROPANE-1,2-DIOL ON PERCUTANEOUS 
ABSORPTION OF TERBINAFINE 
Two penetration enhancers were here compared in order to achieve effective 
delivery of Terbinafine into the skin. Terbinafine is an allylamine with 
antimycotic properties. In this case (5 or 20 %) PG or POL was added to a 
hydrogel containing the API and applied to excised breast skin in Franz 
diffusion cells. The amount API that diffused into the receptor fluid was 
measured using HPLC and related to which penetration enhancer was present, 
in what amount, and how much of the formulation that was left on the skin 
surface. 
 
 
Figure 21 Results from HPLC analysis of Terbinafine concentration in the receptor fluid over 
time. The gel formulations contained 1 % Terbinafine and a varied amount of either enhancer. 
5
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As POL was unheard of as a dermal delivery formulation component, this 
investigation gave new insights into its use and comparability to a known 
penetration enhancer, PG. It was found that both PG and POL increased the 
percutaneous absorption of Terbinafine and that 5% POL resulted in the highest 
absorption Figure 21. Moreover, a very small amount of formulation was left 
on top of the skin. 
 
The higher lipophilicity of POL compared to PG can be a reason why POL was 
the most efficient enhancer in this case, as the API is lipophilic. The low 
amount of POL present in the hydrogel gave a better drug diffusion than the 
higher amount, that is, less is more. This may be due to the low amount of POL 
facilitating interaction between the API and both the enhancer and the 
lipophilic parts of the skin 
5.2. PAPER II 
CUBIC AND SPONGE PHASES FORMED IN TERNARY ETHER LIPID-SOLVENT-
WATER SYSTEMS: PHASE BEHAVIOR AND NMR CHARACTERIZATION 
Liquid crystalline systems are fascinating in their predictability combined with 
ability to surprise. Their uses are far from completely mapped, which we touch 
upon in the introduction of paper II. 
 
The aim of this work was to thoroughly investigate the two GME-POL-water 
and GME-NMP-water systems which are applicable for use in biological fields 
such as protein crystallization, API-delivery etc. 
 
NMP behaved as predicted compared to a previously published diagram with 
PG as solvent [117], that is as an effective solvent with the one-phase areas 
lining up parallel to the GME-NMP base line, except that no lamellar phase 
was found at ambient temperatures. POL, however, showed interesting and 
unanticipated results, regarding the shape of the sponge one phase area, for 
example (see Figure 22). 
 
-55- 
 
Figure 22 The GME-POL-water and GME-NMP-water phase diagrams. The letters in the one-
phase areas denotes: liquid phase, L; lamellar phase, Lα; reversed hexagonal phase, H2; cubic 
phase, I2; and sponge phase, L3. 
 
When looking deeper into this conundrum using NMR, we found that the bola-
shaped POL reside to a slightly higher extent in the water domains of the cubic 
and sponge phases, though prefers the interface between water and lipid. This 
preference is part of the explanation why there is such a large sponge phase 
area compared to comparable phase diagrams, as the presence of POL flattens 
the bilayers. Moreover, the bola shape of the POL molecule may enable POL to 
behave as two solvent molecules through bending around the hydrophilic head 
group of the lipid. This combination makes POL act as an efficient solvent but 
still allows for large ordered liquid crystalline-like bilayered structures. 
 
The presented phase diagrams show two GME-based systems which are 
temperature stable and easy to handle. New applications should be possible to 
find for whoever puts their mind to it. 
5.3. PAPER III 
IN VIVO STUDY OF AN INSTANTLY FORMED LIPID-WATER CUBIC PHASE 
FORMULATION FOR EFFICIENT TOPICAL DELIVERY OF AMINOLEVULINIC ACID 
AND METHYL-AMINOLEVULINATE 
The aim of this study was to improve dermal delivery of ALA and MAL in 
order to enhance the efficacy of PDT. This work builds on a previous study 
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performed in our group [61]. The cubic formulation was in the mentioned study 
found to be very efficient compared to other delivery systems. However, a 
solution to a few problems had to be found in order to obtain a usable system. 
 
Thus, we set out to solve the main issues while maintaining the previous good 
results. First of all; the APIs used in PDT is extremely prone to hydrolysis and 
should be stored in dry form. This 
would imply preferred mixing on site 
before application. With this 
conclusion another issue arose; the 
GMO based cubic phase takes time 
and strenuous mixing to form. Also, 
GMO, which was used in the original 
cubic formulation, hydrolyzes with 
time, and even faster in the presence 
of the API salts. However, the 
solution to the mentioned problems 
lay in replacing GMO with GME. The 
GME cubic phase can be formed 
instantly and is also less viscous and 
thus easier to apply than the GMO 
cubic phase. 
Figure 23 Mixing the formulation, measuring in vivo, and some of the subsequent results. 
 
To obtain a cubic phase using GME, a solvent is required; here either PG or 
POL. An effective solvent flattens the lipid bilayer by organizing itself in the 
border between lipid and water, pushing the lipid head groups apart. This 
favors the cubic structure because of the flatter less strained lipid bilayer. When 
the lipid chains are organized in this way it is possible for the cubic phase to 
hold a higher amount of water [221]. More water and wider channels are 
desirable for topical drug delivery of hydrophilic compounds [109]. 
 
After mixing the on demand formulation and applying it to the skin of the mice 
the subsequent formation of PpIX was monitored. In Figure 23 we see a small 
fraction of the results, which show that the cubic formulations are significantly 
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better at delivering the API into the skin cells. It is noteworthy that Metvix 
contains five times more API than the on demand cubic system tested here. 
 
The results of this paper show an interesting formulation for use in PDT. 
However, a clinical trial has to be performed before human use is possible. As 
the formulation excelled the commercial reference product, we wanted to know 
how efficient the formulation actually is. Thus the work in the following paper 
investigates this further. 
5.4. PAPER IV 
DELIVERY OF SERUM ALBUMIN FROM A CUBIC PHASE INTO VIABLE EPIDERMIS 
STUDIED BY TWO-PHOTON MICROSCOPY 
The aim was to evaluate the ability of the on demand cubic formulation as a 
dermal delivery vehicle for, in this context, large substances. The TPM analysis 
showed penetration of BSA at least 20-30 µm into the skin tissue, but only 
when using the GME-PG-water on demand cubic formulation. 
 
 
Figure 24 The BSA containing cubic phase formulation was applied to the skin surface and the 
permeation was observed using TPM. 
 
For confirmation a second technique was employed. Proteomic methods 
confirmed the results obtained using TPM and revealed that no free fluorophore 
(not attached to BSA) was present in the skin samples.  
 
Enabling diffusion of larger molecules into the skin is beneficial for, e.g., 
needle free vaccination. The depth of diffusion may only be necessary far 
-58- 
enough for the Langerhans cells to reach the delivered API, i.e. deeper tissue 
concentrations may occur earlier and be greater for live skin than predicted by 
passive dermal diffusion ex vivo [222]. 
5.5. WORK IN PROGRESS 
OVERCOMING THE SKIN BARRIER FOR NANOPARTICLES USING NANO-
STRUCTURED CUBIC LIPID SYSTEMS 
The same methodology as for investigating skin delivery of TMR-BSA (paper 
IV and Chapter 5.4.), was performed for QDs of ~17 nm size. The results 
obtained confirmed the results presented in paper IV, and further strengthened 
our theory of how the enhanced penetration came to pass. 
 
TPM was used to envision the diffusion of these large particles into human skin 
after 22 h (34°C) topical application. The formulations compared, all 
containing the same concentration of QDs, was water, water-PG solution, the 
on demand GME-PG-water cubic formulation, GMO-based cubic formulation, 
and hexagonal GME-water phase. 
 
The only case when particles were found within the skin tissue was when the 
GME-based cubic phase was used as delivery vehicle. For the water-PG 
solution a slight penetration at the top few µm gave an indication of its 
importance. Though, most dermal delivery products on the market contain 
penetration enhancers without providing sufficient API absorption. Therefore, a 
combination of the proved effective cubic dermal delivery system ([61] and 
paper III-IV) and an effective penetration enhancer seemed the way to go. 
 
In the same way as the proteomics analysis ensured that BSA was present in 
the samples in paper IV, initial experiments were performed with TEM and 
SEM to detect nanoparticles in the samples. This is ongoing work however and 
no conclusive results has been obtained as of yet. 
 
Besides just wanting to find out how large molecules and particles might be 
deliverable using the cubic formulations, there were other reasons why to 
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choose nanoparticles and in particular PEGylated ones. Nanoparticles 
administered into the body are taken up and accumulated within e.g. cancer 
cells resulting in increased therapeutic effect [223], though when delivered 
intravenously they have been shown to be cleared from the body within 
minutes depending on size, shape, surface charge etc. [224-226]. Thus 
measures have to be taken to hide the particles from the effective immune 
system. Covering the particles with an electrically neutral hydrophilic surface 
layer is a strategy which can extend the circulation half-life with more than 40 
h [227]. This shielding is known as the stealth effect, referring to stealth planes 
[224]. Polyethylene glycol (PEG) is commonly applied to achieve stealth effect 
and additionally reduces the tendency for particles to aggregate by steric 
hindrance [224]. 
 
PEGylated QDs were detected using TPM within viable epidermis when the 
GME-based cubic formulation was used as delivery vehicle. AuNPs could not 
be detected using TPM, thus alternative techniques has to be employed in order 
to detect these particles. Thus, this project continues into the future. 
VISUALIZING DERMAL ABSORPTION OF LIPID CUBIC PHASE FORMULATION FOR 
UNDERSTANDING DERMAL DRUG DELIVERY: A COHERENT ANTI-STOKES RAMAN 
SPECTROSCOPY STUDY 
After finding that the cubic phase was effective as a dermal drug delivery 
vehicle also for large molecules and particles, new questions were raised. Why 
does it work better than the formulations used for comparison? How does the 
cubic phase penetrate into the skin? Do the lipids in the phase migrate into the 
lipid matrix of the SC, or is it the liquid crystalline structure that resembles the 
ordered arrangement of the lipids in the skin that enables interaction? 
 
To answer some of these questions a technique had to be found that could 
provide the opportunity to look into skin and distinguish between the 
formulation, which was added to the surface, and what was already present in 
the skin. In this case fluorescence would not help as the phase itself does not 
fluoresce, thus TPM was ruled out. The samples should still be intact, making a 
number of other techniques inadequate. 
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A technique that works well with lipids and was accessible through another 
research group at the university was coherent anti-Stokes Raman spectroscopy 
(CARS). Looking into published data there were indications that it might be 
possible to distinguish between the lipids in the formulation and the lipids in 
the skin [212]. Not much similar research had been done and the possible 
outcomes were intriguing. 
 
Thus, initial experiments were performed to measure the CARS signal from a 
GME-based cubic phase applied to skin. The difference in CARS spectra 
between GME and the skin was determined (Figure 25), and the lipid signal of 
the applied formulation was followed into the skin (Figure 26). A skin sample 
treated only with water was used for comparison. The most interesting stretch 
vibration was believed to be CH2 (2845 cm-1) [212, 228], as this is found a lot 
in lipids, but measurements were performed to cover the frequency range from 
2835 to 2955 cm-1 (corresponding to pump/probe beam between 817.4 and 
809.5 nm). The experimental set-up has been described before [229]. 
 
 
Figure 25 CARS spectra measured at the skin surface of samples treated with GME-based cubic 
formulation or water. Measurements were conducted between cells (B) and within cells (C). 
 
What we report has to my knowledge not been shown previously and were of 
importance in the understanding of the GME-based cubic formulation as an 
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efficient dermal drug delivery system. Both Figure 25 and Figure 26 show that 
the signal from the lipids originates from around the cells, which of course is 
no surprise, and that the signal is strong in skin wrinkles. The intensity of the 
signal was overall considerably higher with GME present. 
 
Looking closer at the top line of images in Figure 26 it seems as if the lipid 
formulation diffuses downward and is found in part as droplets or depots deep 
into the tissue. The added lipids also continue to enhance the signal in images 
acquired deep within the tissue and spectral examinations showed that the 
signal originated from the added lipids.  
 
 
Figure 26 The top line shows CARS images of skin treated with GME-based cubic formulation at 
various depths. Below are comparative images of skin treated with water. The images are color 
coded: red (2845 cm-1), green (2870 cm-1), blue (2945 cm-1), and the color was scaled so that white 
equals the cubic lipids. The images were retrieved using 20x dry objective, 240x240 µm, 512x512 
pixels. 
 
The results agree with our hypothesis with regards to formulation penetration. 
However, more investigations are needed to thoroughly answer the questions at 
hand. This data must be repeated and compared with the GMO-based cubic 
formulation and other lipid-based formulations. We do not know if this 
diffusion pattern is specific for the GME-based cubic formulation, if it defines 
the diffusion of cubic phases in general, or if other lipid formulations give 
similar results. The latter is unlikely though, as published results of omega-3 oil 
applied to skin did not give a similar result [212]. To visually show the 
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formulation penetrating deep into the tissue without influencing the system 
with fluorophores or other imaging aids are in itself quite remarkable. The 
results presented here are in manuscript form aiming for publication in the near 
future. 
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CONCLUSION 
The results of each study included in this thesis have contributed to 
the postulated hypothesis. The key facts from each study, on which we built the 
hypothesis, are here presented. 
 
Paper I: POL and PG were both found to be efficient percutaneous absorption 
enhancers. 
Paper II: Without the addition of a solvent, GME forms a reversed hexagonal 
phase in excess water. The solvent POL was found to prefer the interface 
between water and lipid, though ends up to a higher extent in the water rich 
domains of the cubic phase compared to the lipid domains. 
Paper III: An effective on demand dermal drug delivery formulation can be 
formed using GME water and PG or POL. The cubic formulations, based on 
GME or GMO, were significantly better at delivering the API into the skin 
cells, compared to the commercial product Metvix. It is noteworthy that Metvix 
contains five times more API than the tested cubic systems. 
Paper IV: TPM and proteomic methods showed that delivery of BSA into 
viable epidermis was possible only when using the GME based cubic 
formulation as delivery vehicle. 
Work in progress: TPM studies of QD penetration into skin tissue confirmed 
the results presented in paper IV, with regard to both penetration and delivery 
vehicle. The preliminary CARS measurements, aiming to distinguish the lipids 
of the formulation (starting in its cubic composition) from the lipids of the skin, 
indicated GME penetration around the cells, in part as droplet-like depots. 
 
From the concluded results and facts previously presented in this thesis, our 
hypothesis can be presented in short: the on demand GME-water-solvent cubic 
formulation adheres well to the skin surface and increases the hydration of the 
tissue. Upon contact with water the solvent is released and the enhancing 
properties act. Simultaneously, due to the loss of solvent, this cubic phase 
transitioned into a reversed hexagonal phase. The increased mobility gained 
enables movement within the skin lipid matrix, further assisted by decreased 
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rigidity due to the fluid lipids of the formulation. Thus, this process continues 
downward and brings the loaded API with it. 
 
Also for the GMO-based cubic phase much of the above is true. However, this 
cubic phase does not transition into a reversed hexagonal phase and is thus less 
mobile. This may be a reason why we did not see increased absorption for BSA 
and nanoparticles while the delivery of the small molecules ALA and MAL 
was as effective. 
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FUTURE OUTLOOK 
The research field in which my projects are included is broad and 
there are a number of ways to go from here. However, first of all the aim 
should be to challenge the postulated hypothesis. Information is needed of how 
the delivery occurs, that is the diffusion of the API and the formulation 
components into skin. One way to elucidate this may be to study the dermal 
delivery of API from the GME-based cubic formulations in the same way as 
Brewer et al. did when finding that transfersomes do not stay intact during 
dermal delivery [83]. Moreover, solvents should be included in the GMO-based 
cubic formulation and the reversed hexagonal GME-based phase in order to 
elucidate if this would enable drug delivery to the same extent as shown for the 
GME-based cubic formulations. 
 
Furthermore, the ongoing work has to be finished. The nanoparticle studies 
only lack the finishing TEM and SEM measurements, which has commenced 
but not been completed. Regarding the CARS study, data must first of all be 
repeated. Thereafter, it should be compared with the GMO-based cubic 
formulation and with other lipid-based formulations in order to visualize 
similarities and differences from which further conclusions can be drawn. 
 
There are a number of research questions related to my performed work that 
would be interesting to look deeper into, for example: 
 Test the on demand cubic system in vivo both through clinical trials of 
ALA-delivery and through animal studies of protein and nanoparticle 
skin penetration and effect. 
 Study the long term effect on the skin barrier after repeated exposure of 
cubic lipid systems. So far most studies are restricted to single exposure 
for maximum 24 hours. As the results of this thesis points towards a 
significant interaction between the lipid constituents of the phase and the 
skin lipids, thorough investigations of this interaction should be 
undertaken not only from an efficacy, but also a safety point of view. 
 Continue the work with sponge phases to provide the protein 
crystallization field with a better understanding of the occurring 
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processes and a more efficient tool to work with. Also, to find other new 
uses for this interesting phase. 
 Combine TPM of, for example, fluorescent proteins with, for example, 
FCS to find an easier way to detect if the fluorophore stays attached to 
the molecule of interest and to follow the diffusion in more detail. 
 Continue the work with TPM and AuNP gradient plates for increased 
understanding and for new applications within, for example, the 
pharmaceutical field. 
 
I hope there will be more people interested in working with these issues in the 
future and that my contribution to the field, however small, may aid in some 
way to an increased understanding. 
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